Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Rare Diseases

Syndrome

Leukemia

Hematologic Neoplasms

Leukemia, Myeloid

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Preleukemia

Myelodysplastic Syndromes

Neoplasms by Histologic Type

Hematologic Diseases

Bone Marrow Diseases

Myeloproliferative Disorders

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

Myeloid Leukemia

Chronic Myeloid Leukemia

Acute Graft Versus Host Disease

Chronic Myeloproliferative Disorders

Antineoplastic Agents

Antirheumatic Agents

Dermatologic Agents

Reproductive Control Agents

All Drugs and Chemicals

Anti-Infective Agents

Micronutrients

Hematinics

Vitamins

Methotrexate

Cyclosporine

Cyclosporins

Mycophenolic Acid

Antilymphocyte Serum

Antimetabolites

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Immunosuppressive Agents

Immunologic Factors

Clotrimazole

Miconazole

Antifungal Agents

Calcineurin Inhibitors

Anti-Bacterial Agents

Antibiotics, Antitubercular

Antitubercular Agents

Folinic Acid

Folate

Vitamin B9

The patients will received HSCT from MSD.

The patients will received HSCT from MUD.

The patients will received HSCT from HRD.

HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.

HSCT from MSD

HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.

HSCT from MUD

HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.

HSCT from HRD

CsA is used in all the patients for GVHD prophylaxis.

Cyclosporin A

MTX is used in all the patients for GVHD prophylaxis.

ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.

Antithymocyte globulin

MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.

Mycophenolate mofetil

Qifa Liu

The purpose of this study is to compare the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from matched sibling donor (MSD),matched unrelated donor (MUD) and haploidentical related donors(HRD) in the treatment of hematologic malignancy.

Currently, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy for a majority of malignant hematologic diseases, especially acute leukemia. HSCT from MSD offers the best results for these diseases, but lack of this donor resource has restricted its wide application. HSCT from MUD provides another option, but MUDs still cannot satisfy all patients due to unsuccessful donor searches. Almost all patients have an available related donor with whom they share a single HLA haplotype (ie, haploidentical related donor), and it owns the advantage of immediate availability, especially for those who urgently need transplantation.The results of transplantation from HRD have improved significantly over the past few years. However, the results from such haploidentical transplantation have not formally been compared with those of transplantation in patients contemporaneously using MSDs and MUDs for hematologic malignancy.

Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Allogeneic Stem Cell Transplantation With Alternative Donor in Treatment of Hematologic Malignancy

The primary endpoint is overall survival within 3 years after HSCT.

Graft-versus-host disease include acute and chronic Graft-versus-host disease

Infection includes bacterial, fungal and viral infections.

Hematopoietic reconstruction includes the time of neutrophil and platelet reconstruction.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy	NCT02487069	Acute Leukemia Chronic Myeloid... Myelodysplastic...	HSCT from MSD HSCT from MUD HSCT from HRD Cyclosporin A Methotrexate Antithymocyte g... Mycophenolate m...	18 Years - 60 Years	Nanfang Hospital, Southern Medical University
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy	NCT02487069	Acute Leukemia Chronic Myeloid... Myelodysplastic...	HSCT from MSD HSCT from MUD HSCT from HRD Cyclosporin A Methotrexate Antithymocyte g... Mycophenolate m...	18 Years - 60 Years	Nanfang Hospital, Southern Medical University
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy	NCT02487069	Acute Leukemia Chronic Myeloid... Myelodysplastic...	HSCT from MSD HSCT from MUD HSCT from HRD Cyclosporin A Methotrexate Antithymocyte g... Mycophenolate m...	18 Years - 60 Years	Nanfang Hospital, Southern Medical University

Spots Global Cancer Trial Database for hsct from hrd